Comparison of Lubiprostone and Placebo for the Relief of Constipation From Constipating Medications
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01096290|
Recruitment Status : Terminated (Number of needed participants could not be obtained)
First Posted : March 31, 2010
Results First Posted : September 9, 2020
Last Update Posted : November 20, 2020
- Study Details
- Tabular View
- Study Results
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Constipation||Drug: lubiprostone Drug: Matched placebo||Phase 4|
Lubiprostone is a novel chloride channel activator that increases intestinal fluid secretion and motility. It is FDA approved and indicated for treatment of chronic idiopathic constipation and recently, constipation-predominant irritable bowel syndrome.
The Physicians Desk Reference lists over 90 Brand medications with reported incidence associated with constipation over 3%. Little data are available about treatment responses. A recent publication by our group reported treatment success for medication constipation using polyethylene glycol. Since ongoing studies are addressing the role of lubiprostone in opioid constipation, this work will be enrolling medication constipation study subjects not using opioids.
In this study, patients who meet diagnostic criteria for constipation will be randomized to receive 28 days of treatment with lubiprostone 24mcg twice a day. Data will be collected to evaluate therapeutic outcome.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||23 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Comparison of Lubiprostone and Placebo for the Relief of Constipation From Constipating Medications|
|Study Start Date :||April 2010|
|Actual Primary Completion Date :||September 2012|
|Actual Study Completion Date :||September 2012|
Experimental: Lubiprostone 24mcg BID for 30 days
24mcg BID, capsule, oral 30days
Other Name: Amitiza
Placebo Comparator: Placebo
Placebo, matched, blinded
Drug: Matched placebo
Twice daily for 30days, oral
Other Name: Placebo, sugar pill
- Relief of Constipation Defined by Modified ROME Criteria [ Time Frame: 30 days ]Subjects will report symptoms by questionnaire
- Frequency [ Time Frame: 30 days ]Subjects will report stool frequency by questionnaire
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||19 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||Yes|
- Adult male or female outpatient age 19 or older.
Patients meet International Congress of Gastroenterology (ROME III) clinical criteria for constipation*:
Must include two or more of the following:
- Straining in > 1/4 defecations;
- Lumpy or hard stools > 1/4 defecations;
- Sensation of incomplete evacuation in 1/4 defecations;
- Sensation of anorectal obstruction/blockage in > 1/4 defecations;
- <3 defecations/week.
- Loose stools are rarely present without the use of laxatives.
- There are insufficient criteria for irritable bowel syndrome. *Criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis.
- Use of one or more of listed medications known to cause constipation.
- If female and of childbearing potential, patient must be surgically sterilized or using oral contraceptives, depot contraceptives, intrauterine device, or testifies that she is monogamous with a vasectomized partner, or practices abstinence and will continue to do so during the duration of study. Mandatory compliance is required. Serum pregnancy tests will be performed at screening and during needed follow-up. Negative results will be received before inclusion and administration of first study dose. If pregnancy occurs during the trial, the investigator is notified immediately resulting in prompt discontinuation.
- Study subjects must not have received lubiprostone for more than 72 hours.
- Written informed consent.
- Known or suspected obstruction, gastric retention, ileus, perforation, fecal impaction or inflammatory bowel disease.
- Severe diarrhea.
- Prior small bowel or colonic resection or colostomy.
- Weight < 80 lbs.
- If the patient has constipation that according to the investigator's clinical judgment is not the result of constipating medications but is suffering from a secondary cause including but limited to factors that are dietary, neurologic, congenital, diabetic or hypothyroid.
- Positive stool hemoccult (Can be included if colonoscopic evaluation is subsequently negative).
- Significant cardiac, renal or hepatic insufficiency.
- Pregnant or expecting to become pregnant within 120 days of study enrollment.
- Lactating or breast feeding.
- Subjects using opioid medications.
- Subjects who in the opinion of the investigator would be unable to comply adequately with the study plan.
- Use of investigational drugs in the last 30 days.
- Patients with known allergy to lubiprostone.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01096290
|United States, Alabama|
|USA Pavilion at Infirmary West|
|Mobile, Alabama, United States, 36693|
|Principal Investigator:||Jack A DiPalma, M.D.||University of South Alabama College of Medicine|
|Responsible Party:||University of South Alabama|
|Other Study ID Numbers:||
|First Posted:||March 31, 2010 Key Record Dates|
|Results First Posted:||September 9, 2020|
|Last Update Posted:||November 20, 2020|
|Last Verified:||November 2020|
Signs and Symptoms, Digestive
Chloride Channel Agonists
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action